Customize your JAMA Network experience by selecting one or more topics from the list below.
Chiang C, Yang Y, You S, Lai M, Chen C. Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan. JAMA. 2013;310(9):974–976. doi:10.1001/jama.2013.276701
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Hepatitis B virus (HBV) infection causes infant fulminant hepatitis (IFH), and chronic HBV infection may progress to chronic liver disease (CLD) and hepatocellular carcinoma (HCC). Taiwan launched a nationwide HBV immunization program for newborns in July 1984,1 which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts.2- 4 The mortality of CLD before and after HBV immunization has never been examined. We assessed the 30-year outcomes of the immunization program.
From July 1984 to June 1986, the immunization program covered only newborns with high-risk mothers who were seropositive for HBV surface antigen. Coverage was extended to all newborns in July 1986, preschool children in July 1987, and primary school children in 1988-1990. Recombinant HBV vaccines replaced plasma-derived vaccines in 1992. The immunization coverage rates for birth cohorts from 1984 to 2010 was 88.8% to 96.9%.2,5
The mortality of IFH, CLD, and HCC and the incidence of HCC were compared among birth cohorts born before and after the launch of the program. The National Death Certificates Database (1977-2011) was used to derive the mortality rates of IFH (International Classification of Diseases, Ninth Revision [ICD-9] code 570), CLD (ICD-9 code 571), and HCC (ICD-9 codes 1550 and 1552); the National Cancer Registry Database (1977-2009) was used to derive the incidence rates of HCC (International Classification of Diseases for Oncology code C220).6 Infant fulminant hepatitis was analyzed in birth cohorts to 2009-2011, whereas other outcomes were analyzed in birth cohorts to 2001-2004 (age range: 5-29 years in 2009). To control sex and duration of HBV infection, sex-adjusted or age- and sex-adjusted incidence and mortality rate ratios were calculated using Poisson regression models (SAS version 9.2; SAS Institute Inc). Two-sided P< .05 was considered statistically significant. This study was approved by the data release review board of the Bureau of Health Promotion, which waived the requirement for informed consent.
Infant fulminant hepatitis mortality rates and sex-adjusted rate ratios declined significantly for infants born from 1977-1980 to 2009-2011 (Table). The decline was greatest from 1981-1984 to 1985-1988 and from 1989-1992 to 1993-1996, coincident with the launch of the national immunization program in 1984 and the change to recombinant vaccines in 1992. Compared with 1977-1980, the sex-adjusted rate ratio declined to 0.88 (95% CI, 0.65-1.21) in 1981-1984, 0.46 (95% CI, 0.31-0.69) in 1985-1988, and 0.03 (95% CI, 0.01-0.24) in 2009-2011.
There was a continuous decline in age- and sex-adjusted rate ratios of CLD and HCC mortality and HCC incidence for birth cohorts born after implementation of the program. The birth cohort born in 1981-1984, which received HBV vaccines at preschool ages instead of early infancy, had significantly lower CLD and HCC mortality and HCC incidence than those born in 1977-1980. The age- and sex-adjusted rate ratio in 2001-2004 was 0.11 (95% CI, 0.02-0.80) for CLD mortality, 0.08 (95% CI, 0.02-0.34) for HCC mortality, and 0.20 (95% CI, 0.06-0.65) for HCC incidence.
Males had significantly higher CLD and HCC mortality and HCC incidence than females in most age groups (Figure). The 1985-2006 birth cohorts had significantly lower CLD and HCC mortality and HCC incidence rates than those born in 1977-1984 for both sexes.
The mortality of IFH in vaccinated birth cohorts decreased by more than 90% from 1977-1980 to 2009-2011, which was greater than the previously reported reduction (approximately 70%) from 1975-1984 to 1985-1998.4 This long-term, high-coverage immunization program was associated with lower IFH mortality through increasing individual and herd immunity of vaccinated cohorts. From 1977-1980 to 2001-2004, the age- and sex-adjusted rate ratios for individuals aged 5 to 29 years decreased by more than 90% for CLD and HCC mortality and by more than 80% for HCC incidence, which were higher than the previously reported reduction (70%) in HCC incidence for youth aged 6 to 19 years.3
The national HBV therapy program launched in November 2003 may also be contributing to the reduction in risk of IFH, CLD, and HCC; however, this contribution is likely minimal because few members of the study cohorts were eligible for therapy. Hepatitis B virus immunization in infancy has been associated with a reduction in the risk of IFH, CLD, and HCC in Taiwan.
Corresponding Author: Chien-Jen Chen, ScD, Genomics Research Center, Academia Sinica, 128 Academia Rd, Sec 2, Taipei 11529, Taiwan (firstname.lastname@example.org).
Author Contributions: Drs Chiang and Chen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Chiang, You, Chen.
Acquisition of data: Chiang, Yang, You, Lai, Chen.
Analysis and interpretation of data: Chiang, Yang, You, Chen.
Drafting of the manuscript: Chiang, You.
Critical revision of the manuscript for important intellectual content: Chiang, Yang, You, Lai, Chen.
Statistical analysis: Chiang, Yang, You.
Administrative, technical, or material support: Chiang, You.
Study supervision: Lai, Chen.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chen reported serving as a consultant to Bristol-Myers Squibb, Merck Sharp & Dohme, GlaxoSmithKline, and Roche; receiving grants from Bristol-Myers Squibb and Roche; and receiving payment for lectures from Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche. No other disclosures were reported.
Funding/Support: This work was supported by grants from the Bureau of Health Promotion, Department of Health, Executive Yuan, Taiwan, and Academia Sinica.
Role of the Sponsor: The Bureau of Health Promotion, Department of Health, Executive Yuan, Taiwan, and Academia Sinica had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.